- Home
- BRIA vs ANVS Comparison
BRIA vs ANVS Comparison
Compare BRIA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- ANVS
- Stock Information
- Founded
- BRIA 2011
- ANVS 2008
- Country
- BRIA Singapore
- ANVS United States
- Employees
- BRIA N/A
- ANVS 6
- Industry
- BRIA
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- BRIA
- ANVS Health Care
- Exchange
- BRIA NYSE
- ANVS Nasdaq
- Market Cap
- BRIA 73.0M
- ANVS 31.2M
- IPO Year
- BRIA 2024
- ANVS 2020
- Fundamental
- Price
- BRIA $2.58
- ANVS $1.71
- Analyst Decision
- BRIA
- ANVS Strong Buy
- Analyst Count
- BRIA 0
- ANVS 5
- Target Price
- BRIA N/A
- ANVS $37.00
- AVG Volume (30 Days)
- BRIA 19.0K
- ANVS 460.2K
- Earning Date
- BRIA 03-18-2025
- ANVS 03-31-2025
- Dividend Yield
- BRIA N/A
- ANVS N/A
- EPS Growth
- BRIA N/A
- ANVS N/A
- EPS
- BRIA 92.24
- ANVS N/A
- Revenue
- BRIA $55,755,669.00
- ANVS N/A
- Revenue This Year
- BRIA N/A
- ANVS N/A
- Revenue Next Year
- BRIA N/A
- ANVS N/A
- P/E Ratio
- BRIA $0.03
- ANVS N/A
- Revenue Growth
- BRIA 8.03
- ANVS N/A
- 52 Week Low
- BRIA $2.30
- ANVS $1.53
- 52 Week High
- BRIA $4.38
- ANVS $20.00
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- ANVS 19.82
- Support Level
- BRIA N/A
- ANVS $1.57
- Resistance Level
- BRIA N/A
- ANVS $1.77
- Average True Range (ATR)
- BRIA 0.00
- ANVS 0.18
- MACD
- BRIA 0.00
- ANVS 0.07
- Stochastic Oscillator
- BRIA 0.00
- ANVS 8.38
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.